US 12,404,323 B2
Antibody capable of binding to thymic stromal lymphopoietin and use thereof
Jinping Shi, Shanghai (CN); Hua Ying, Shanghai (CN); Tingting Li, Shanghai (CN); Yifang Wang, Shanghai (CN); Guimei Yang, Shanghai (CN); Hu Ge, Shanghai (CN); and Weikang Tao, Shanghai (CN)
Assigned to JIANGSU HENGRUI MEDICINE CO., LTD, Lianyungang (CN); and SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD, Shanghai (CN)
Appl. No. 17/615,970
Filed by JIANGSU HENGRUI MEDICINE CO., LTD., Lianyungang (CN); and SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., Shanghai (CN)
PCT Filed Jun. 3, 2020, PCT No. PCT/CN2020/094154
§ 371(c)(1), (2) Date Dec. 2, 2021,
PCT Pub. No. WO2020/244544, PCT Pub. Date Dec. 10, 2020.
Claims priority of application No. 201910480579.9 (CN), filed on Jun. 4, 2019.
Prior Publication US 2022/0340654 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 11/06 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/24 (2013.01) [A61P 11/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. A method for treating a human patient having a TSLP-related disease, the method comprising administering to the human patient a therapeutically effective amount of an anti-TSLP antibody comprising:
(i) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 26, SEQ ID NO: 94 and SEQ ID NO: 28, respectively; and,
(ii) a light chain variable region comprising LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 29, SEQ ID NO: 113 and SEQ ID NO: 31, respectively;
wherein the TSLP-related disease is asthma, or nasal polyposis.